Previous 10 | Next 10 |
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BioMarin To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 11, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BioMarin To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 9, 2021) - Faruqi & Faruqi, LLP, a leading national securities law...
BioMarin has 6 commercialised assets in the rare disease space, targeting e.g. lysosomal storage diseases. The company is on track for ~$1.8bn of revenues in FY21, and importantly, a small non-GAAP net income, reversing years of heavy losses. The company also has a PDUFA date on N...
Image source: The Motley Fool. BioMarin Pharmaceutical inc (NASDAQ: BMRN) Q3 2021 Earnings Call Oct 27, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: BioMarin Pharmaceutical inc (BMRN) Q3 2021 Earnings Call Transc...
BioMarin Pharmaceutical Inc. (BMRN) Q3 2021 Earnings Conference Call October 28, 2021, 4:30 PM ET Company Participants J.J. Bienaime – Chairman and Chief Executive Officer Traci Mc Carty – Vice President of Investor Relations Jeff Ajer – Executive Vice President and Chief...
BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates - Strong Commercial Launch of VOXZOGO™ for the Treatment of Children with Achondroplasia Ages 2 and Older Underway across Europe; U.S. Review Proceeding, Target Action Date Tracking to November ...
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States District Court for the Northern D...
BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , Oct. 12, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bi...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations Harold S. Bernstein, M.D., Ph.D. Named Senior Vice President, Chief Medical Officer and Head of Clini...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease PR Newswire Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, C...
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...